The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Patients with schizophrenia often fail to respond to an initial course of therapy. This study systematically reviewed the societal and economic burden of treatment-resistant schizophrenia (TRS). Studies that described patients with TRS published 1996-2012 were included if they collected primary data on clinical, social, or economic outcomes. All studies were independently reviewed and extracted by at least two investigators. Sixty-five studies were identified. Almost 60% (SD 18%) of patients failed to achieve response after 23 weeks on antipsychotic drug therapy. Patients with TRS had high rates of smoking (56%), alcohol abuse (51%), substance abuse (51%), and suicide ideation (44%). The incidence of severe adverse events to treatment was 4% (SD 7%). Mean quality of life for patients who were unresponsive or intolerant to treatment was ∼20% lower than that of patients in remission. Annual costs for patients with schizophrenia are $15 500-$22 300 and are 3-11-fold higher for patients with TRS. TRS remains common and costly, despite availability of many treatment options, and contributes to a significant loss in patient quality of life. Although estimates in the literature vary greatly, TRS conservatively adds more than $34 billion in annual direct medical costs in the USA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the USA, annual direct medical costs associated with TRS are conservatively estimated at over $34 billion. 41”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [41]
In the citing paper
“the mean quality of life is estimated to be 20% lower in TRS compared with non-TRS. 41 Mean quality of life is approximately 25-40% lower in patients with TRD compared with patients who respond to treatment or who are in remission; 46”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [41]
In the citing paper
“It has been estimated that hospitalisation costs and total health resource utilisations for TRS are 10-fold higher than those for non-TRS and that up to 80% of the total yearly health costs associated with schizophrenia in the USA are attributed to TRS. 41”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [41]
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156 · cited 6×
“In addition, 20–30% fail to respond to treatment, and a similar fraction of treatmentadherent patients relapse despite sustained maintenance therapy (Kane et al., 1988, 2007; Conley and Kelly, 2001).”
BackgroundInfluentialSchizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality
McGrath, J., Saha, S., Chant, D., & Welham, J. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn001 · Cited by 2,280 · cited 2×
“…with schizophrenia are more than twice those in the general population, and life expectancy is 12–15 years shorter than that of the general population, often as a result of personal neglect, poverty, and suicide (Barbato, 1998; Mcgrath et al., 2008; Van Os and Kapur, 2009; Wahlbeck et al., 2011).”
BackgroundRoom, R., Babor, T., & Rehm, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17870-2 · Cited by 1,625
Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population
Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K., Isometsä, E., Pirkola, S., Partonen, T., Tuulio-Henriksson, A., Hintikka, J., Kieseppä, T., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.1.19 · Cited by 1,516 · cited 1×
“3% (Perala et al., 2007).”
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105 · cited 2×
“…be indicative of the TR population (Table 6) (Wyatt et al., 1995; Blieden et al., 1998; Percudani et al., 1999; Mccombs et al., 2000; Fuller et al., 2002; Wu et al., 2005; Jones et al., 2006; Ascher-Svanum et al., 2008; Ascher-Svanum et al., 2010; Nicholl et al., 2010; Peng et al., 2011a, 2011b).”
BackgroundDeterminants of Medication Compliance in Schizophrenia: Empirical and Clinical Findings
Fenton, W. S., Blyler, C. R., & Heinssen, R. K. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.637 · Cited by 957 · cited 1×
“Patient noncompliance almost certainly contributes to treatment nonresponse in schizophrenia, as better drug adherence is associated with a better prognosis and outcomes (Fenton et al., 1997; Jaeger et al., 2012).”
BackgroundMarwaha, S., & Johnson, S. (2004) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-004-0762-4 · Cited by 922
Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders
Wahlbeck, K., Westman, J., Nordentoft, M., Gissler, M., & Laursen, T. M. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.085100 · Cited by 623 · cited 2×
“…with schizophrenia are more than twice those in the general population, and life expectancy is 12–15 years shorter than that of the general population, often as a result of personal neglect, poverty, and suicide (Barbato, 1998; Mcgrath et al., 2008; Van Os and Kapur, 2009; Wahlbeck et al., 2011).”
BackgroundThe Economic Burden of Schizophrenia in the United States in 2002
Wu, E. Q., Birnbaum, H. G., Shi, L., Ball, D. E., Kessler, R. C., Moulis, M., & Aggarwal, J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0906 · Cited by 614 · cited 3×
“…be indicative of the TR population (Table 6) (Wyatt et al., 1995; Blieden et al., 1998; Percudani et al., 1999; Mccombs et al., 2000; Fuller et al., 2002; Wu et al., 2005; Jones et al., 2006; Ascher-Svanum et al., 2008; Ascher-Svanum et al., 2010; Nicholl et al., 2010; Peng et al., 2011a, 2011b).”
BackgroundHealth, United States, 2010; with special feature on death and dying
Bernstein, A. B., Bilheimer, L. T., & Makuc, D. M. (2011) · Cited by 498
Barriers to Employment for People With Schizophrenia
Rosenheck, R., Leslie, D., Keefe, R., McEvoy, J., Swartz, M., Perkins, D., Stroup, S., Hsiao, J. K., Lieberman, J., & CATIE Study Investigators Group (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.411 · Cited by 465 · cited 1×
“Unauthorized reproduction of this article is prohibited. schizophrenia in the USA are reported to exceed 70% (Marwaha and Johnson, 2004; Rosenheck et al., 2006; Marwaha et al., 2007; Salkever et al., 2007).”
BackgroundThe Burden of Mental Disorders
Eaton, W. W., Martins, S. S., Nestadt, G., Bienvenu, O. J., Clarke, D., & Alexandre, P. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn011 · Cited by 460 · cited 2×
“In addition, the high annual total costs associated with schizophrenia in the USA, estimated at more than $75 billion in 2012 dollars (Wyatt et al., 1995; Wu et al., 2005; Eaton, 2008), underscore the large economic impact of the disease.”
BackgroundRates and correlates of employment in people with schizophrenia in the UK, France and Germany
Marwaha, S., Johnson, S., Bebbington, P., Stafford, M., Angermeyer, M. C., Brugha, T., Azorin, J.-M., Kilian, R., Hansen, K., & Toumi, M. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.020982 · Cited by 370 · cited 1×
“Unauthorized reproduction of this article is prohibited. schizophrenia in the USA are reported to exceed 70% (Marwaha and Johnson, 2004; Rosenheck et al., 2006; Marwaha et al., 2007; Salkever et al., 2007).”
BackgroundManagement of treatment resistance in schizophrenia
Conley, R. R., & Kelly, D. L. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01271-9 · Cited by 352 · cited 4×
“Although 70–80% of adult patients with TRS respond to treatment (Kane et al., 1988, 2007; Conley and Kelly, 2001), only 17% of adolescent patients with schizophrenia were well at follow-up, indicating its lasting effects (Werry et al., 1991).”
BackgroundInfluentialWERRY, J. S., MCCLELLAN, J. M., & CHARD, L. (1991) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199105000-00017 · Cited by 344 · cited 2×
“Although 70–80% of adult patients with TRS respond to treatment (Kane et al., 1988, 2007; Conley and Kelly, 2001), only 17% of adolescent patients with schizophrenia were well at follow-up, indicating its lasting effects (Werry et al., 1991).”
BackgroundBurroughs, V. J., Maxey, R. W., & Levy, R. A. (2002) · PubMed Central · Cited by 289
The cost of relapse and the predictors of relapse in the treatment of schizophrenia
Ascher-Svanum, H., Zhu, B., Faries, D. E., Salkever, D., Slade, E. P., Peng, X., & Conley, R. R. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-2 · Cited by 275 · cited 4×
“8 times higher healthcare costs than those with no prior relapse (Ascher-Svanum et al., 2010).”
BackgroundInfluentialComorbid substance use and age at onset of schizophrenia
Barnes, T. R. E., Mutsatsa, S. H., Hutton, S. B., Watt, H. C., & Joyce, E. M. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.104.007237 · Cited by 271 · cited 3×
“By comparison, general patients with schizophrenia were estimated to have a 55–65% smoking rate (Barnes et al., 2006; Bobes et al., 2010; Ferreira et al., 2010), 27–35% alcohol abuse and 28–35% substance abuse rates (Blanchard et al., 2000; Kavanagh et al., 2002; Barnes et al., 2006).”
BackgroundOlanzapine Compared With Chlorpromazine in Treatment-Resistant Schizophrenia
Conley, R. R., Tamminga, C. A., Bartko, J. J., Richardson, C., Peszke, M., Lingle, J., Hegerty, J., Love, R., Gounaris, C., & Zaremba, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.914 · Cited by 245 · cited 2×
“%) and a range from 0 to 74% (for patients with TRS on chlorpromazine to ziprasidone, respectively) (Table 4) (Conley et al., 1998; Loebel et al., 2007).”
BackgroundSubstance use disorders in schizophrenia: review, integration, and a proposed model
Blanchard, J. (2000) · Clinical Psychology Review · doi:10.1016/s0272-7358(99)00033-1 · Cited by 240 · cited 2×
“By comparison, general patients with schizophrenia were estimated to have a 55–65% smoking rate (Barnes et al., 2006; Bobes et al., 2010; Ferreira et al., 2010), 27–35% alcohol abuse and 28–35% substance abuse rates (Blanchard et al., 2000; Kavanagh et al., 2002; Barnes et al., 2006).”
BackgroundEconomics and Schizophrenia: The Real Cost
Davies, L. M., & Drummond, M. F. (1994) · British Journal of Psychiatry · doi:10.1192/s0007125000293161 · Cited by 213 · cited 1×
“Davies and Drummond (1994) found similar results: care for the 10% of patients with schizophrenia who have a longterm disabling course accounts for 80% of total lifetime direct costs for schizophrenia within Great Britain; 75% of these are because of inpatient or residential care, whereas less than…”
BackgroundCost effectiveness of clozapine in neuroleptic-resistant schizophrenia
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.11.1630 · Cited by 211 · cited 3×
“A study on TRS costs by Meltzer et al. (1993) published before this review’s 1996–2011 inclusion criteria found that patients with TRS incurred $104 434 in hospitalization and outpatient costs.”
BackgroundTollefson, G. D., Birkett, M. A., Kiesler, G. M., & Wood, A. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01026-x · Cited by 202
An economic evaluation of schizophrenia-1991
Wyatt, R. J., Henter, I., Leary, M. C., & Taylor, E. (1995) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00789054 · Cited by 200 · cited 4×
“Annual per-patient costs for general schizophrenia, in comparison, are reported between $15 483 and an excess of $22 313 over a nonschizophrenic population (Wyatt et al., 1995; Fuller et al., 2002; Wu et al., 2005; Peng et al., 2011a).”
BackgroundInfluentialUsing a pharmacogenomic algorithm to guide the treatment of depression
Hall-Flavin, D. K., Winner, J. G., Allen, J. D., Jordan, J. J., Nesheim, R. S., Snyder, K. A., Drews, M. S., Eisterhold, L. L., Biernacka, J. M., & Mrazek, D. A. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.99 · Cited by 185 · cited 2×
“Variations in genes that produce aberrant hepatic enzyme activities and suboptimal drug effector proteins can predict greater healthcare utilization and costs (Winner et al., 2013) as well as poorer antidepressant efficacy (Hall-Flavin et al., 2012).”
BackgroundMalhotra, A. K. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.191 · Cited by 185 · cited 1×
“…risk for clozapine-induced agranulocytosis (CIA) (Athanasiou et al., 2011), and variants in genes for the serotonin 5-HT2C receptor (Sicard et al., 2010) and the melanocortin MCR4 receptor (Malhotra et al., 2012) predict risk for weight gain induced by clozapine and other antipsychotic agents.”
BackgroundBobes, J., Arango, C., Garcia-Garcia, M., & Rejas, J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1030 · Cited by 181 · cited 2×
“By comparison, general patients with schizophrenia were estimated to have a 55–65% smoking rate (Barnes et al., 2006; Bobes et al., 2010; Ferreira et al., 2010), 27–35% alcohol abuse and 28–35% substance abuse rates (Blanchard et al., 2000; Kavanagh et al., 2002; Barnes et al., 2006).”
BackgroundSubstance Misuse in Patients with Schizophrenia: Epidemiology and Management
Kavanagh, D. J., McGrath, J. J., Saunders, J. B., Dore, G., & Clark, D. (2002) · Drugs · doi:10.2165/00003495-200262050-00003 · Cited by 179 · cited 2×
“By comparison, general patients with schizophrenia were estimated to have a 55–65% smoking rate (Barnes et al., 2006; Bobes et al., 2010; Ferreira et al., 2010), 27–35% alcohol abuse and 28–35% substance abuse rates (Blanchard et al., 2000; Kavanagh et al., 2002; Barnes et al., 2006).”
BackgroundSuzuki, T., Remington, G., Mulsant, B. H., Uchida, H., Rajji, T. K., Graff-Guerrero, A., Mimura, M., & Mamo, D. C. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.013 · Cited by 176 · cited 2×
“…despite one or more antipsychotic trials of adequate length and dosage (Breier and Hamilton, 1999; Lindenmayer et al., 2002; Kane et al., 2011; Suzuki et al., 2012), in which case failure to respond to at least one antipsychotic agent more thoroughly captures those patients for whom some…”
BackgroundSmoking and therapeutic response to clozapine in patients with schizophrenia
McEvoy, J. P., Freudenreich, O., & Wilson, W. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00377-1 · Cited by 172
Partial compliance in schizophrenia and the impact on patient outcomes
Llorca, P.-M. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.07.012 · Cited by 163 · cited 1×
“Compliance rates are as low as 50% after 6 months of therapy initiation, and patients take less than 60% of prescribed antipsychotic doses (Llorca, 2008).”
BackgroundKane, J. M., Meltzer, H. Y., Carson, W. H., McQuade, R. D., Marcus, R. N., Sanchez, R., & Aripiprazole Study Group (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0206 · Cited by 163 · cited 3×
“Although 70–80% of adult patients with TRS respond to treatment (Kane et al., 1988, 2007; Conley and Kelly, 2001), only 17% of adolescent patients with schizophrenia were well at follow-up, indicating its lasting effects (Werry et al., 1991).”
BackgroundInfluentialRisperidone in Treatment-Refractory Schizophrenia
Wirshing, D. A., Marshall, Jr., Green, M. F., Mintz, J., Marder, S. R., & Wirshing, W. C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1374 · Cited by 148
Athanasiou, M. C., Dettling, M., Cascorbi, I., Mosyagin, I., Salisbury, B. A., Pierz, K. A., Zou, W., Whalen, H., Malhotra, A. K., Lencz, T., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05527yel · Cited by 132 · cited 4×
“Identifying patients at greater risk for CIA could lessen the need for regular monitoring and potentially allow a large proportion of the 2.5 million patients at low risk for CIA to switch to clozapine.”
BackgroundInfluentialDiet, diabetes and schizophrenia: Review and hypothesis
Peet, M. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.47.s102 · Cited by 130 · cited 1×
“Poor diet and less attention to personal hygiene and health are well-known and common manifestations of TRS that contribute to more frequent comorbidities (Peet, 2004; Mayo Clinic, 2012).”
BackgroundKane, J. M., Meltzer, H. Y., Carson, W. H., et al. (2007) · PubMed · Cited by 128
Winner, J., Allen, J. D., Anthony Altar, C., & Spahic-Mihajlovic, A. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.2 · Cited by 128 · cited 1×
“Variations in genes that produce aberrant hepatic enzyme activities and suboptimal drug effector proteins can predict greater healthcare utilization and costs (Winner et al., 2013) as well as poorer antidepressant efficacy (Hall-Flavin et al., 2012).”
BackgroundSelf-citationSalkever, D. S., Karakus, M. C., Slade, E. P., Harding, C. M., Hough, R. L., Rosenheck, R. A., Swartz, M. S., Barrio, C., & Yamada, A. M. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.3.315 · Cited by 128 · cited 1×
“Unauthorized reproduction of this article is prohibited. schizophrenia in the USA are reported to exceed 70% (Marwaha and Johnson, 2004; Rosenheck et al., 2006; Marwaha et al., 2007; Salkever et al., 2007).”
BackgroundBreier, A. F., & Hamilton, S. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00291-1 · Cited by 126 · cited 4×
“the presence of pervasive positive symptoms despite one or more antipsychotic trials of adequate length and dosage (Breier and Hamilton, 1999; Lindenmayer et al., 2002; Kane et al., 2011; Suzuki et al., 2012), in which case failure to respond to at least one antipsychotic agent more thoroughly captures those patients…”
BackgroundInfluentialCiapparelli, A., Dell’Osso, L., di Poggio, A. B., Carmassi, C., Cecconi, D., Fenzi, M., Chiavacci, M. C., Bottai, M., Ramacciotti, C., & Cassano, G. B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0416 · Cited by 123 · cited 1×
“Ciapparelli et al. (2003) reported that 65% of patients with TRS in an Italian population were unemployed, compared with a 10.4% unemployment rate in the general Italian population in 2000 (Index Mundi, 2011).”
ResultInfluentialAscher-Svanum, H., Nyhuis, A. W., Faries, D. E., Kinon, B. J., Baker, R. W., & Shekhar, A. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm134 · Cited by 104 · cited 4×
“…be indicative of the TR population (Table 6) (Wyatt et al., 1995; Blieden et al., 1998; Percudani et al., 1999; Mccombs et al., 2000; Fuller et al., 2002; Wu et al., 2005; Jones et al., 2006; Ascher-Svanum et al., 2008; Ascher-Svanum et al., 2010; Nicholl et al., 2010; Peng et al., 2011a, 2011b).”
BackgroundInfluentialPolymorphisms of the HTR2C Gene and Antipsychotic-Induced Weight Gain: An Update and Meta-Analysis
Sicard, M. N., Zai, C. C., Tiwari, A. K., Souza, R. P., Meltzer, H. Y., Lieberman, J. A., Kennedy, J. L., & Müller, D. J. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.123 · Cited by 102 · cited 1×
“…at increased risk for clozapine-induced agranulocytosis (CIA) (Athanasiou et al., 2011), and variants in genes for the serotonin 5-HT2C receptor (Sicard et al., 2010) and the melanocortin MCR4 receptor (Malhotra et al., 2012) predict risk for weight gain induced by clozapine and other…”
BackgroundSelf-citationBurden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective
Nicholl, D., Akhras, K. S., Diels, J., & Schadrack, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003658956 · Cited by 85 · cited 1×
“…be indicative of the TR population (Table 6) (Wyatt et al., 1995; Blieden et al., 1998; Percudani et al., 1999; Mccombs et al., 2000; Fuller et al., 2002; Wu et al., 2005; Jones et al., 2006; Ascher-Svanum et al., 2008; Ascher-Svanum et al., 2010; Nicholl et al., 2010; Peng et al., 2011a, 2011b).”
BackgroundCiapparelli, A., Dell'Osso, L., Pini, S., Chiavacci, M. C., Fenzi, M., & Cassano, G. B. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0502 · Cited by 82
Sava, F. A., Yates, B. T., Lupu, V., Szentagotai, A., & David, D. (2009) · Journal of Clinical Psychology · doi:10.1002/jclp.20550 · Cited by 82 · cited 1×
“In comparison with other mental disorders, TRS has a less severe utility weight (i.e. quality of life, 0.61) than major depressive disorder patients who do not respond to therapy (0.3–0.55) (Nuijten, 2001; Sava et al., 2009; Benedict et al., 2010).”
BackgroundInfluentialChanpattana, W., & Kramer, B. A. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00330-4 · Cited by 72 · cited 1×
“Consistent with its greater prophylactic effect in resistant patients, electroconvulsive therapy resulted in an 88% response rate after 3 weeks (Chanpattana and Kramer, 2003).”
BackgroundOlanzapine in Treatment-Refractory Schizophrenia
Martin, J., Gomez, J.-C., Bernardo, E. G., Cuesta, M. J., Álvarez, E., Manuel Gurpegui, A., & The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1103 · Cited by 71
Fijal, B. A., Kinon, B. J., Kapur, S., Stauffer, V. L., Conley, R. R., Jamal, H. H., Kane, J. M., Witte, M. M., & Houston, J. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.24 · Cited by 68 · cited 1×
“…variants among Caucasians and non-Caucasian populations show population differences in drug metabolism and response that are not simply because of under-representation of certain genotypes in ethnic groups (Burroughs et al., 2002; Subramaniam et al., 2007; Fijal et al., 2009; Bigos et al., 2011).”
BackgroundGenetic variation in CYP3A43 explains racial difference in olanzapine clearance
Bigos, K. L., Bies, R. R., Pollock, B. G., Lowy, J. J., Zhang, F., & Weinberger, D. R. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.38 · Cited by 68 · cited 1×
“…variants among Caucasians and non-Caucasian populations show population differences in drug metabolism and response that are not simply because of under-representation of certain genotypes in ethnic groups (Burroughs et al., 2002; Subramaniam et al., 2007; Fijal et al., 2009; Bigos et al., 2011).”
BackgroundSacchetti, E., Galluzzo, A., Valsecchi, P., Romeo, F., Gorini, B., & Warrington, L. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.02.017 · Cited by 66
Facilitating Clinical Implementation of Pharmacogenomics
Mrazek, D. A., & Lerman, C. (2011) · JAMA · doi:10.1001/jama.2011.1010 · Cited by 64 · cited 1×
“…early diagnosis, and improved education for clinicians and patients, when combined with more consistent processes for regulatory requirements and reimbursements of new therapeutics and diagnostics, will help to reduce the burden of TRS in the USA (Mrazek and Lerman, 2011; Wilke and Dolan, 2011).”
BackgroundOlivares, J. M., Peuskens, J., Pecenak, J., Resseler, S., Jacobs, A., Akhras, K. S., & on behalf of the e-STAR study group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903149306 · Cited by 62 · cited 1×
“Symptom severities of patients with TRS differ little at the end of drug trials from those of treatment-naive schizophrenia patients at the beginning of drug trials (Olivares et al., 2009; Macfadden et al., 2011).”
BackgroundLindenmayer, J.-P., Czobor, P., Volavka, J., Lieberman, J. A., Citrome, L., Sheitman, B., Chakos, M., & McEvoy, J. P. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1011 · Cited by 59 · cited 4×
“…as the presence of pervasive positive symptoms despite one or more antipsychotic trials of adequate length and dosage (Breier and Hamilton, 1999; Lindenmayer et al., 2002; Kane et al., 2011; Suzuki et al., 2012), in which case failure to respond to at least one antipsychotic agent more…”
BackgroundInfluentialGenetics and Variable Drug Response
Wilke, R. A., & Dolan, M. E. (2011) · JAMA · doi:10.1001/jama.2011.998 · Cited by 56 · cited 2×
“Pharmacogenomic tests are anticipated to help guide medication selection and dosing, hasten response rates, increase compliance, and improve quality of life for patients, and thereby reduce the escalating rates in annual health expenditures (Wilke and Dolan, 2011).”
BackgroundAscher-Svanum, H., Peng, X., Faries, D., Conley, R., & Schuh, K. (2011) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s16061 · Cited by 54 · cited 15×
“Schizophrenia is a treatable condition, with many therapeutic alternatives, yet more than half of those with schizophrenia do not receive appropriate treatment (Kane et al., 1988; Barbato, 1998).”
InfluentialAn Open Comparison of Clozapine and Risperidone in Treatment-Resistant Schizophrenia
Flynn, S. P., MacEwan, G. W., Altman, S., Kopala, L. C., Fredrikson, D. H., Smith, G. N., & Honer, W. G. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979291 · Cited by 51
Suzuki, T., Uchida, H., Watanabe, K., Nakajima, S., Nomura, K., Takeuchi, H., Tanabe, A., Yagi, G., & Kashima, H. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.959 · Cited by 49
Clinical aspects of super-refractory schizophrenia: a 6-month cohort observational study
Neto, J. H., & Elkis, H. (2007) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462007000300007 · Cited by 44
Suzuki, T., Mihara, K., Nakamura, A. M., Nagai, G., Kagawa, S., Nemoto, K., Ohta, I., Arakaki, H., Uno, T., & Kondo, T. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3182031021 · Cited by 43 · cited 1×
“…genetic polymorphisms for hepatic metabolizing enzymes could be used to help adjust doses or allow for selection of alternative antipsychotics for those who are poor or ultrarapid metabolizers, thereby increasing efficacy and minimizing treatment resistance (Kang et al., 2009; Suzuki et al., 2011).”
BackgroundKane, J. M., Potkin, S. G., Daniel, D. G., & Buckley, P. F. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03733yel · Cited by 42 · cited 5×
“Sacchetti et al. (2009) found that 75% of patients experienced adverse events, and Kane et al. (2011) found that 6% of patients had serious adverse events.”
BackgroundInfluentialDavies, L. M., Barnes, T. R. E., Jones, P. B., Lewis, S. W., Gaughran, F., Hayhurst, K. P., Markwick, A., & Lloyd, H. M. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00280.x · Cited by 39 · cited 2×
“Davies et al. (2008) found a 0.”
BackgroundInfluentialThe Implications of Using US-Specific EQ-5D Preference Weights for Cost-Effectiveness Evaluation
Noyes, K., Dick, A., & Holloway, R. (2007) · Medical decision making · doi:10.1177/0272989x07301822 · Cited by 38
Macfadden, W., DeSouza, C., Crivera, C., Kozma, C. M., Dirani, R. D., Mao, L., & Rodriguez, S. C. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-167 · Cited by 36 · cited 1×
“Symptom severities of patients with TRS differ little at the end of drug trials from those of treatment-naive schizophrenia patients at the beginning of drug trials (Olivares et al., 2009; Macfadden et al., 2011).”
BackgroundInitiating Clozapine Treatment in the Outpatient Clinic: Service Utilization and Cost Trends
Luchins, D. J., Hanrahan, P. A., Shinderman, M. S., Lagios, L., & Fichtner, C. G. (1998) · Psychiatric Services · doi:10.1176/ps.49.8.1034 · Cited by 36 · cited 3×
“…costsa Hospitalizationsb Total health resource usec TRS (Blieden et al., 1998; Buckman and Malan, 1999; Percudani et al., 1999) TRS/TR SA mixed (Luchins et al., 1998) Schizophrenia (Peng et al., 2011a) USA average (2010) Healthcare costs per patient-year for patients with TRS, TRS/TR SA, and…”
BackgroundBenedict, Á., Arellano, J., Cock, E. D., & Baird, J. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.04.017 · Cited by 33 · cited 2×
“As expected, patients with schizophrenia in remission have a better utility weight (0.75) than patients with TRS, and slightly better than those with major depression who respond to therapy (0.64–0.7) (Nuijten, 2001; Benedict et al., 2010).”
BackgroundResultInfluentialPharmacologic treatment of adolescent and child schizophrenia
Young, C., & Findling, R. L. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.1.53 · Cited by 32 · cited 1×
“More research is needed to understand the full burden and more effective treatments for child-onset and adolescent-onset schizophrenia (Young and Findling, 2004).”
BackgroundMcIntyre, R. S., Cragin, L. S., Sorensen, S. V., Naci, H., Baker, T., & Roussy, J. (2010) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2009.01189.x · Cited by 31 · cited 1×
“Davies et al. (2008) found a 0.61 utility for patients with schizophrenia unresponsive or intolerant to current treatment, whereas Mcintyre et al. (2010) found that patients in remission have a utility of 0.75, an increase of 0.14.”
BackgroundInfluentialMetabolic differences between Asian and Caucasian patients on clozapine treatment
Subramaniam, M., Ng, C. H., Chong, S., Mahendran, R., Lambert, T. J. R., Pek, E., & Huak, C. Y. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.842 · Cited by 30 · cited 1×
“…variants among Caucasians and non-Caucasian populations show population differences in drug metabolism and response that are not simply because of under-representation of certain genotypes in ethnic groups (Burroughs et al., 2002; Subramaniam et al., 2007; Fijal et al., 2009; Bigos et al., 2011).”
BackgroundJaeger, S., Pfiffner, C., Weiser, P., Kilian, R., Becker, T. M., Längle, G., Eschweiler, G. W., Croissant, D., Schepp, W., & Steinert, T. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.03.033 · Cited by 28 · cited 1×
“Patient noncompliance almost certainly contributes to treatment nonresponse in schizophrenia, as better drug adherence is associated with a better prognosis and outcomes (Fenton et al., 1997; Jaeger et al., 2012).”
BackgroundSchizophrenic syndromes and clozapine response in treatment-resistant schizophrenia
Molina, V., Catalina, M. L., García-Noblejas, J. A., & Cuesta, P. (1998) · Psychiatry Research · doi:10.1016/s0165-1781(97)00129-7 · Cited by 26
Service Use and Costs Among VA Patients With Schizophrenia Taking Risperidone or Olanzapine
Fuller, M. A., Shermock, K. M., Secic, M., Laich, J. S., & Durkin, M. B. (2002) · Psychiatric Services · doi:10.1176/appi.ps.53.7.855 · Cited by 25 · cited 4×
“Annual per-patient costs for general schizophrenia, in comparison, are reported between $15 483 and an excess of $22 313 over a nonschizophrenic population (Wyatt et al., 1995; Fuller et al., 2002; Wu et al., 2005; Peng et al., 2011a).”
BackgroundInfluentialPercudani, M., Fattore, G., Galletta, J., Mita, P., Contini, A., & Altamura, A. C. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb07225.x · Cited by 25 · cited 5×
“Examining each study individually, hospitalization costs were 87 and 69% of total health resource usage in Blieden et al. (1998) and Percudani et al. (1999), respectively.”
BackgroundInfluentialChiu, N., Yang, Y. K., Chen, P. S., Chang, C., Lee, I. H., & Lee, J. (2003) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2003.01151.x · Cited by 24
Assessment of Clinical Guidelines for Continuation Treatment in Major Depression
Nuijten, M. J. C. (2001) · Value in Health · doi:10.1046/j.1524-4733.2001.44053.x · Cited by 23 · cited 2×
“As expected, patients with schizophrenia in remission have a better utility weight (0.75) than patients with TRS, and slightly better than those with major depression who respond to therapy (0.64–0.7) (Nuijten, 2001; Benedict et al., 2010).”
BackgroundResultInfluentialDoes akathisia influence psychopathology in psychotic patients treated with clozapine?
Nair, C., Josiassen, R. C., Abraham, G., Stanilla, J. K., Tracy, J. I., & Simpson, G. M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00146-2 · Cited by 20
Clozapine for refractory schizophrenia: the Illinois experience.
Buckman, R. W., & Malan, R. D. (1999) · PubMed · Cited by 19
Ferreira, L., Belo, A., & Abreu‐Lima, C. (2010) · PubMed · Cited by 18
Ziprasidone in Treatment-Resistant Schizophrenia
Loebel, A. D., Khanna, S., Rajadhyaksha, S., SIU, C. O., Giller, E. L., & Potkin, S. G. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0902 · Cited by 18 · cited 2×
“%) and a range from 0 to 74% (for patients with TRS on chlorpromazine to ziprasidone, respectively) (Table 4) (Conley et al., 1998; Loebel et al., 2007).”
BackgroundAntipsychotic prescribing in Black and White hospitalised patients
Connolly, A., Taylor, D. M., Sparshatt, A., & Cornelius, V. R. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109387841 · Cited by 16 · cited 1×
“However, antipsychotic prescribing is practiced similarly between ethnicities (Connolly et al., 2011), which may need to be reconsidered to improve treatment responsiveness in ethnic populations.”
BackgroundSelf-citationBlieden, N., Flinders, S., Hawkins, K., Reid, M. M., Alphs, L. D., & Arfken, C. L. (1998) · Psychiatric Services · doi:10.1176/ps.49.12.1590 · Cited by 16 · cited 10×
“Examining each study individually, hospitalization costs were 87 and 69% of total health resource usage in Blieden et al. (1998) and Percudani et al. (1999), respectively.”
BackgroundResultInfluentialMcCombs, J. S., Luo, M., Johnstone, B. M., & Shi, L. (2000) · Value in Health · doi:10.1046/j.1524-4733.2000.33004.x · Cited by 14 · cited 4×
“Untreated patients had costs 1.2 times higher ($8000 more) than treated patients (Mccombs et al., 2000).”
BackgroundInfluentialNonresponse to clozapine and premorbid functioning in treatment refractory schizophrenia
Kelly, D. L., Feldman, S. M., Boggs, D. L., Gale, E., & Conley, R. R. (2009) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2009.07.003 · Cited by 14
A follow-up study of a population of schizophrenic patients treated with clozapine
Bourin, M., Guitton, B., Dailly, É., Hery, P., & Jolliet, P. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00213-5 · Cited by 12
Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
Peng, X., Ascher‐Svanum, H., Faries, D., Stauffer, V. L., Kollack‐Walker, S., Kinon, B. J., & Kane, J. M. (2011) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s16859 · Cited by 11
Cited by
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Fregni, F., El-Hagrassy, M. M., Pacheco-Barrios, K., Carvalho, S., Leite, J., Simis, M., Brunelin, J., Nakamura-Palacios, E. M., Marangolo, P., Venkatasubramanian, G., et al. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa051 · Cited by 605
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives
Nucifora, F. C., Woznica, E., Lee, B. J., Cascella, N., & Sawa, A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.016 · Cited by 304
Siskind, D., Orr, S., Sinha, S., Yu, O., Brijball, B., Warren, N., MacCabe, J. H., Smart, S. E., & Kisely, S. (2022) · The British Journal of Psychiatry · doi:10.1192/bjp.2021.61 · Cited by 255
“2 These cases of treatment-resistant schizophrenia (TRS) are associated with high levels of functional impairment, 3 healthcare usage, societal costs 4 and physical health comorbidity.”
Metadata
- Authors
- Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C.
- Affiliations
- University of Toronto (CA)
- Stanford Medicine (US)
- Corresponding author
- Hornberger, John C.
- Venue
- International Clinical Psychopharmacology
- Published
- 2014-03
- Volume
- 29
- Issue
- 2
- Pages
- 63-76
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2036480935
- Cited by
- 392
- References
- 84
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 44 · 2023: 39 · 2022: 37 · 2021: 33 · 2020: 35 · 2019: 38 · 2018: 35 · 2017: 16 · 2016: 21 · 2015: 18 · 2014: 6
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant schizophrenia, economic burden, social burden, antipsychotic treatment response, treatment intolerance, smoking, alcohol abuse, substance abuse, suicidal ideation, adverse drug reactions, quality of life, health care costs, direct costs
- MeSH terms
- Costs and Cost Analysis, Drug Resistance, Humans, Psychiatric Status Rating Scales, Quality of Life, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Comorbidity, Randomized Controlled Trials as Topic, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.